Refild: 1, There and Back Agaim: A Review of Residency and Return Migrations in Sharks, with Implications for Population Structure and Management.

Chapman DD, Feldheim KA, Papastamatiou Y, Hueter RE

STUDY CHARACTERISTICS

1. REF ID#
Year study was conducted (NR if not reported)
3. Location study was conducted in
□ Not reported
Canada
USA
☐ Mexico
New Zealand
Australia
Brazil
Sweden
Germany
Estonia Estonia
France
Hungary
□ Italy
□ Netherlands
United Kingdom
Finland
Norway
☐ Ibadan, Nsukka, Jos
☐ Kenya
Belgium
China
Argentina
Perimanently add an answer to this question ()

1 of 5 2019-05-30, 1:10 p.m.

_	-	
Form	Prev	view

4. Breed		
Not reported		
Holstein/Friesian		
☐ Jersey		
Mixed breed dairy		
Norwegian Red or Swedish		
Finnish Ayrshire		
Montbeliarde		
Perimanently add an answer to this question ()		
5. Farm type		
Commercial dairy		
Research/university dairy		
Not reported		
6. Number of farms enrolled (NR if not reported)		
6. Number of farms enrolled (NK if not reported)		
7. Farm eligibility requirements (NR if not reported)		
8. Eligibility - lactation number		
all lactations /not stated		
first lactation only		
2 + lactation only		
less than 6 lactations		
less than 4 actations		
ess than 8 lactations		
ess than 3 lactations		
less than 5		
Perimanently add an answer to this question ()		
9. Eligibility - no clinical mastitis events in number of days (NR if not reported)		
10. Eligibility:		
no clinical mastitis events in the current lactation		

2 of 5 2019-05-30, 1:10 p.m.

Describe the most complicated trial a	rm				
one antibiotic, one route					
> 1 antibotic, one route					
one antibiotic, > 1 route					
> 1 antibiptic, > 1 route					
Clear Response (I)					
Arm 1	Ar	rm 2		Arm 3	
Select an Answer	•	Select an Answer	-	Select an Answer	
Perimanentily add an ainswer to the	niis auuastiiom (1)	Perimainently add ain ainswer to th	iis augstion ()	Perimanently add an answer to this question	n (1)
ii Ciiiiilaiiileiiilay aaa aiiii aiiii.swcii aa a	iiis questiviii (y	ii ciiiiidiiiciiidiy dada diii diiiiswcii co diii	iis quescionii (v	The communication of the second secon	W
Arm 1 route	Ar	rm 2 route		Arm 3 route	
Select an Answer	•	Select an Answer	T	Select an Answer	
Perrmanently add an answer to the	niis qwestiiom ()	Perimainently add ain ainswer to th	iis qwestiiom ()	Perimanently add ain answer to this question	ı (0)
Arm 1 frequency	Ar	rm 2 frequency		Arm 3 frequency	
Select an Answer	_	Select an Answer	-	Select an Answer	
Perimanentily add an ainswer to the	niis auuestiiom (1)	Perimainently add ain ainswer to th	iis awestiiom ()	Perimanently add an answer to this question	n (0)
i cililary and all all all all all all all all all al	question w		iis questioni (ii	, in Chilliann Children and the Country of the Coun	
Arm 1 duration	Ar	rm 2 duration		Arm 3 duration	
Select an Answer	-	Select an Answer	-	Select an Answer	
Perimanentily add an ainswer to the	niis auuastiiom (1)	Perimainently add ain ainswer to th	iis augstion ()	Perimanently add an answer to this question	n (1)
ii CiiiiiwaiiiCiiiwy waa wiii wiii.swcii w ui	iiis questiviii ()	ii ciiiiidiiiciiidiy dada diii diiiiswcii co diii	iis quescionii (v	The communication of the second secon	W
D. CTEDIO: 0.016.611					
BACTERIOLOGIC CU	KŁ				
Overaniana					
Organisms	Californ City	ahastar sa . C. Carunahastarium sa	C Enteroba	stavan - Entavasassus en - Eschavishia cali	
				cter sp. Enterococcus sp. Escherichia coli coplasma Negative/no growth Nocardia sp	
			_	Staph sp. Coagulase negative staph (CNS)	
_		rmidis Strep sp. Strep aglacti erium pyogenes, Corynebacterium py	_	canis Strep dysgalactiae Strep mutans Yeast Other (specify)	\neg
Saley assens Traperena pyogo	v canobact	pyogonos, corynesacterium p	, - 95//	The state of the s	
ALL CASES # Events #	Arm 2 # Ev	vents Arm 3			
# Events Arm 1 (1st Tx cure)					

3 of 5

Total Number in Arm 1 Total Number in Arm 2 Total Number in Arm 3
Bacillus sp. # Events Arm 2 # Events Arm 3 # Events Arm 1 (1st Tx cure)
Total Number in Arm 1 Total Number in Arm 2 Total Number in Arm 3
CLINICAL CURE
Is clinical cure rate available BY bacterial organism?
Yes
O No
Clear Response ()
Clear Response ()
Cllear Response (i) # Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure ———————————————————————————————————
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure ———————————————————————————————————
Events Arm 1 (1st Tx cure) - Clinical cure # Events Arm 2 - Clinical cure # Events Arm 3 - Clinical cure

4 of 5 2019-05-30, 1:10 p.m.

https://v2dis-prod.evidencepartners.com/Submit/RenderForm.php	https://v2dis-	prod.evidence	oartners.com/	Submit/Re	enderForm.	php
---	----------------	---------------	---------------	-----------	------------	-----

Blinded	Randomized	Allocation concealment
Yes	Yes	Yes
O No	O No	No
Source		
Journal artic	le	
Conference	manuscript/abstract	
Thesis		
Other (speci	fy)	
Comment about of	data	

Copyright © 2008-2019, Evildemce Partmers IInc., All Rights Reserved I Release Notes (https://releasemotes.evildemcepartmers.com/imdex.php/Distiller/Version_2/Release_Notes)
Loading time: 0.352 seconds

5 of 5